story of the week
Use of Elexacaftor–Tezacaftor–Ivacaftor in Patients With Cystic Fibrosis Without a F508del CFTR Variant
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
Lancet Respir Med 2024 Nov 01;12(11)888-900, PR Burgel, I Sermet-Gaudelus, E Girodon, I Durieu, V Houdouin, C Audousset, J Macey, D Grenet, M Porzio, M Murris-Espin, P Reix, M Baravalle, C Belleguic, L Mely, J Verhille, L Weiss, M Reynaud-Gaubert, M Mittaine, R Hamidfar, S Ramel, L Cosson, B Douvry, I Danner-Boucher, P Foucaud, C Roy, E Burnet, C Raynal, MP Audrezet, J Da Silva, C MartinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.